Irwin Naturals Bringing Its Household Name Brand to the Psychedelic Mental Health SpaceTryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETFMindMed and Liechti Lab Provide Results from their Psilocybin R&D CollaborationPsyched Wellness Announces Inclusion in AdvisorShares Psychedelics Exchange Traded Fund (ETF)Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating DisordersPsyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan
Back

Field Trip Has A Warchest Of Cash To Propel R&D and M&A Moving Forward

Mar 22, 2021 • 7:30 AM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

If you have not been following Field Trip Health Ltd. (CSE: FTRP) (OTCQX: FTRPF), you may want to put the company on your radar after it closed a massive private placement.

Last week, Field Trip reported to have closed a previously announced $95 million bought deal short form prospectus offering. The financing included the full exercise of the underwriters’ over-allotment option and we consider this to be a positive for the company.

Field Trip is considered to be a leader in the development and delivery of psychedelic therapies, and we are excited to see how the management team uses the proceeds to advance the business.

Field Trip CEO Joseph del Moral stated that the closing of the financing is an important milestone for the business as it provides the resources that are needed to execute on previously announced initiatives. We believe the size of the financing is a testament to the strength of the platform and will closely monitor the business on a going forward basis.

Soleus Capital Management was the lead investor in the financing, and we believe that Field Trip is backed by smart money. The firm stated that it believes that Field Trip is positioned to establish itself as a global leader in the delivery and development of psychedelic therapies for depression and other mental health indications with high unmet need.

We are favorable on the size of the total addressable market (TAM) of the indications that Field Trip is focused on. The company plans to use the proceeds from the financing for the ongoing development of the “FT-104” novel psychedelic development program, the opening of new Field Trip Health centers, and for working capital and general corporate purposes.

Going forward, we expect Field Trip to accelerate the rollout of its branded health centers across North America and Europe. The company has the proceeds to fund this initiative and will still have enough resources to capitalize on unique and accretive growth opportunities.

We believe that Field Trip has been nothing short of an execution story and will monitor how the story advances from here. If you are interested in learning more about Field Trip Health, please send an email to support@mushroomstocks.com with the subject “Field Trip Health” to be added to our distribution list.

For the fastest access to data on Field Trip Health, you can set up a free account or sign up for our free newsletter!

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link